Prof. Brian Greenwood is bestowed the title ‘Knights Bachelor’ by HRH Queen Elizabeth for his services to malaria research in Africa
In a career spanning several decades, both in the UK and in Africa, Prof. Greenwood’s contribution to malaria research can be described as nothing short of multidisciplinary. He was amongst the first to identify and demonstrate the utility of bednets in the control of malaria in randomized clinical trials and has made significant contributions to the trials of a number of potential malaria vaccines.
Importantly, for MMV’s work, Brian was also one of the first to conduct trials of artemisinin combination therapies (ACTs) in children in Africa, namely Coartem® (artemether/lumefantrine). Coartem, developed by Novartis, is now the first-line treatment for uncomplicated malaria in many countries. Given the success of Coartem in treating patients with malaria, Novartis and MMV teamed up to reformulate the medicine and develop the first high-quality ACT especially for children – Coartem®Dispersible. To date, more than 92 million treatments of this child-friendly medicine have been despatched to 35 disease-endemic countries.
Brian, currently Manson Professor of Clinical Tropical Medicine at the London School of Hygiene and Tropical Medicine, first joined MMV’s Expert Scientific Advisory Committee (ESAC) in 2006 and, on completion of his full term, stepped back in 2010. Nonetheless, with such a wealth of experience in malaria research to offer he remains on hand to input into MMV’s work.
“Having made significant contributions to each of the key tools we have against malaria, I can think of no worthier a recipient than Brian for such an honour,” said David Reddy, CEO, MMV. “With the benefit of his wisdom we look forward to continuing his good work in developing the next generation of antimalarials.”
Awarded on merit, the rank of Knights Bachelor is the most ancient, dating back as far as the reign of King Henry III (1216-1272).
The title of Knights Bachelor has also been awarded to Dr Andrew Witty, CEO of GlaxoSmithKline (GSK) for his services to the UK economy and the UK pharmaceutical industry. GSK is developing a vaccine for malaria and working together with MMV to develop a radical cure for relapsing malaria.